TVTX - Travere Therapeutics, Inc.
IEX Last Trade
17.78
0.075 0.422%
Share volume: 23,687
Last Updated: Thu 26 Dec 2024 08:30:20 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$17.70
0.08
0.42%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.12%
1 Month
-10.13%
3 Months
13.90%
6 Months
107.64%
1 Year
81.65%
2 Year
-13.22%
Key data
Stock price
$17.78
DAY RANGE
$16.98 - $17.76
52 WEEK RANGE
$5.50 - $20.33
52 WEEK CHANGE
$82.04
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Eric M. Dube
Region: US
Website: travere.com
Employees: 460
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: travere.com
Employees: 460
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.
Recent news